Research institute in
Schlieren

55 companies in Research institute based in Schlieren — name and year of registration from the commercial register.

Companies

50 of 55 companies

Molecular Partners AG

Since 2004 · 101–500 empl.4.9(11)

Molecular Partners AG is a biotechnology company researching and developing therapeutics based on its DARPin protein technology. Its work focuses on targeted radiopharmaceuticals for cancer and DARPin-based immunotherapies.

Research instituteDARPin therapeuticsRadio-DARPin therapeuticsSwitch-DARPin therapeutics

InSphero AG

Since 2009 · 51–100 empl.5.0(9)

The core activity of InSphero is the development and provision of 3D cell culture technologies and solutions for drug discovery and research. In particular, the company focuses on the development of 3D cell culture systems, such as the Akura system, which enables researchers to create so-called spheroids to test the effect of drugs on cells. InSphero's solutions are used in various fields, including liver safety research, liver disease research, islet biology, oncology, and immunology.

Research institute3D Cell Culture Tools3D In Vitro Liver Safety Testing3D In Vitro Oncology and Immunology

LimmaTech Biologics AG

Since 2015 · 51–100 empl.4.8(4)

LimmaTech Biologics AG develops vaccines against infections caused by pathogens resistant to antimicrobial treatments. Its work uses a proprietary multivalent vaccine platform and other approaches, with vaccine candidates advancing through clinical development.

Research instituteVaccine developmentProprietary vaccine platformBioconjugation technology

Zippsafe AG

Since 2016 · 11–20 empl.5.0(6)

Zippsafe AG develops and sells smart, space-saving locker systems for employee changing rooms. Its products also include software for locker management and solutions to transport and digitally document patients’ belongings.

Research instituteSmart locker systems for employeesDigital locker room managementTransport of patient belongings

BIO-TECHNOPARK Schlieren-Zürich

Since 2009 · 1–10 empl.5.0(6)

BIO-TECHNOPARK Schlieren-Zürich is a science park for life sciences companies and institutions. It promotes knowledge and technology transfer and supports company formation and development through coaching, networking, and access to laboratory, office, and research infrastructure.

Industry associationOffice and laboratory space rentalRental of event venues and meeting roomsAdvisory, coaching and support

Kuros Biosciences AG

Since 1995 · 51–100 empl.4.0(7)

Kuros Biosciences AG is a biotechnology company developing biologic technologies for bone healing. Its products include MagnetOs, a bone graft substitute for use in spine and extremity procedures.

Research instituteMagnetOs Spine TechnologiesMagnetOs Extremities TechnologiesProject Fusion

indie Technologies Switzerland AG

Since 2003 · 101–500 empl.5.0(4)

indie Technologies Switzerland AG operates in photonics, offering optical components, light sources and integrated solutions. Its portfolio includes SLED modules, laser diodes, fiber-optic components and optical filters for applications such as sensing, imaging and optical communications.

Research institutePhotonics componentsLight sources

Mabylon AG

Since 2011 · 11–20 empl.4.7(3)

Mabylon AG is a biotechnology company that discovers and develops antibody-based therapeutics for allergies, inflammatory disorders and neurological diseases. It identifies and engineers antibodies from human immune repertoires and advances its own drug candidates.

Research instituteAntibody-based drug discoveryTherapeutics for allergiesTherapeutics for inflammation and neurodegeneration

Acytronix GmbH

Since 2024 · 1–10 empl.5.0(14)

Acytronix GmbH develops and sells equipment and consumables for the purification of extracellular vesicles. It also provides services for separating and characterizing biological nanoparticles.

Research institutePurification of extracellular vesiclesEV isolation devices and kits (PMED)Custom purification services

GeoSIG AG

Since 1992 · 1–10 empl.

GeoSIG AG develops and manufactures instruments and systems for monitoring earthquakes, vibrations and structures. Its products include sensors, recorders, data acquisition systems and software, complemented by consulting for applications such as monitoring bridges, dams and buildings.

Research instituteMeasuring instruments for earthquake and vibration monitoringAcceleration sensorsSeismometer

DUALSYSTEMS BIOTECH AG

Since 2000 · 1–10 empl.

DUALSYSTEMS BIOTECH AG provides proteomics services to industry and academia. Using its LRC-TriCEPS and HATRIC-LRC platforms, it identifies target and off-target proteins on living cell surfaces and offers pretests and target confirmation.

Research instituteLRC-TriCEPSPretest TriCEPS Service and KitFlow-TriCEPS

PolyGEL Tec AG

Since 2002 · 1–10 empl.

Research instituteNo identifiable own services

Redbiotec AG

Since 2006 · 11–20 empl.

Redbiotec AG is a biotechnology company that engineers microorganisms for research and applications in oncology and gene therapy. It also develops and produces proteins and genetic materials for the biopharmaceutical and food industries, and works on therapeutic vaccines, casein proteins and DNA products.

Research instituteKey proteins and genetic materialsCasein proteinsCell-free manufacturing of genetic materials

Microbe Investigations AG

Since 2012 · 21–50 empl.

Microbe Investigations AG is a contract research organization and microbiology testing laboratory. It provides efficacy testing and research and development services for products in areas such as textiles, disinfectants, cosmetics, plastics and coatings, including testing against insects, bacteria, viruses and fungi.

Research instituteEntomology Testing ServicesAntimicrobial Testing for TextilesDisinfectant Efficacy Testing

Axanton Technology GmbH

Since 2013 · 1–10 empl.

Axanton Technology GmbH develops a technology platform for producing MEMS, a class of therapeutic biomolecules targeting cell-membrane signalling. Its development pipeline includes A-144, a drug candidate intended to affect cell degeneration.

Research instituteDevelopment of MEMS TherapeuticsMEMS Technology Platform and IPLicensing of MEMS Rights

PharmaBiome AG

Since 2015 · 11–20 empl.

PharmaBiome AG develops biotechnology-based therapies using the intestinal microbiome. It designs and cultivates bacterial consortia intended to restore microbiome functions, including for conditions such as inflammatory bowel disease.

Research instituteDevelopment of microbiome-based therapiesDevelopment and production of function-based bacterial consortiaCollaboration in microbiome R&D

Repertoire Immune Medicines (Switzerland) AG

Since 2018 · 21–50 empl.

Repertoire Immune Medicines (Switzerland) AG develops immune-based medicines for cancer and autoimmune diseases. Its approaches include T-cell receptor bispecific medicines, mRNA cancer vaccines and mRNA-based tolerizing therapies developed using the DECODE platform.

Research instituteDECODE PlatformTCR-Bispecific Immune MedicinesmRNA Cancer Vaccines

Athebio AG

Since 2019 · 21–50 empl.

Athebio AG is a biotechnology company developing a DARPin platform and drug discovery engine for targeted biotherapeutics. It partners on applications including targeted gene delivery, radiotherapy and immuno-oncology.

Research instituteAthebody® platformDrug-Discovery-EnginePartnering for biotherapeutic development projects

Synergene Biotech GmbH

Since 2001 · 1–10 empl.

Synergene Biotech GmbH provides services for the life sciences community and develops custom projects. The website lists services including sequencing (overnight sequencing), barcode and postpay sample submission, primer lists, software tools, and support for sample preparation, laboratory techniques and data analysis.

Research institute

Fabas Foods AG

Since 2021 · 11–20 empl.

The core activity of Fabas Foods AG is the development of raw material solutions and ingredient systems for milk alternatives, with the goal of creating a more sustainable food future.

Research institute

InterAx Biotech AG

Since 2016 · 11–20 empl.5.0(2)

The core activity of InterAx Biotech AG is the development of solutions in the field of computer-aided chemistry and systems biology, particularly in the context of GPCR signaling pathways and medicinal chemistry. The company combines expertise in computer science, biology, chemistry, and pharmacy to develop innovative approaches for the development of drugs and therapies.

Research instituteDeep Signal™ platformGPCR drug discovery and hit-to-lead developmentMechanistic modeling for drug development

BiognoSYS AG

Since 2008 · 51–100 empl.5.0(1)

BiognoSYS AG provides contract research services in proteomics for biomarker research and drug development. It also develops and sells proteomics software, peptide kits, and sample preparation reagents.

Research instituteProteomics CRO ServicesProteomics SoftwareProteomics Consumables

Microcaps AG

Since 2019 · 21–50 empl.4.0(5)

Microcaps AG develops and operates a microfluidic platform for encapsulating ingredients for the cosmetics, food and pharmaceutical industries. Its activities include developing and manufacturing alcohol-free, water-based fragrances containing microencapsulated perfume oils.

Research instituteEthanol-free Perfume PearlsEthanol-free Body MistCosmetic Microencapsulation

Polaroid Therapeutics AG

Since 2023 · 1–10 empl.

Polaroid Therapeutics AG develops biotechnology products for antimicrobial applications in healthcare. Its products include APT™ polymer technology and POLTX_Fiber, a gelling fiber wound dressing with antimicrobial functionality.

Research instituteWound care with POLTX_Fiber™Antimicrobial Polymer Technology (APT™)Medical coatings

Neurimmune Subone AG

Since 2007 · 1–10 empl.5.0(1)

Neurimmune Subone AG is a biopharmaceutical company that translates human immune memory into antibody therapeutics. It develops monoclonal antibody candidates for indications including Alzheimer’s disease, amyotrophic lateral sclerosis, spinal cord injury, ATTR cardiomyopathy and type‑2 diabetes, applying its Reverse Translational Medicine™ (RTM™) technology platform and pursuing discovery, early clinical development and strategic partnerships.

Research instituteAntibody therapeuticsAmyloid depletionReverse Translational Medicine™ (RTM™)

Veralit AG

Since 1984 · 1–10 empl.4.0(10)

Veralit AG develops and applies technical surface coatings for components, including electroless nickel-phosphorus coatings and other functional coating systems. The company also repairs worn or incorrectly machined machine parts and supports customers in developing application-specific solutions.

Research instituteTechnical surface coatingsChemical nickel platingVeralit NISLIDE®

hemotune AG

Since 2017 · 21–50 empl.5.0(3)

hemotune AG develops a platform for targeted magnetic separation using magnetic nanoparticles. Its technology is intended for applications in blood purification, including sepsis therapy and combination gene therapy, as well as bioseparation and processing.

Research instituteMagnetic nanoparticle platformHemoBeadsHemoSystem

rqmicro AG

Since 2013 · 11–20 empl.3.0(2)

rqmicro AG develops solutions for rapid microbiological analysis and quantification of bacteria in water and other liquid samples. Its offerings include flow cytometry instruments and test kits, as well as laboratory and contract R&D services for water, industrial and quality-control applications.

Research instituteMicrobiology Testingrqmicro.COUNTCloud Solution

arcoris bio AG

Since 2024 · 11–20 empl.

arcoris bio AG develops and supplies MUSE technology for sensitive, multiplex biomarker detection. Its offerings include ready-to-use immunofluorescence kits, custom solutions for protein and RNA detection, and licensing and technology integration solutions.

Research instituteimmunoMUSE® kitsCustom solutionsPartnerships

Neurimmune AG

Since 2017 · 11–20 empl.5.0(1)

Neurimmune AG is a clinical-stage biopharmaceutical company developing therapeutic antibodies. Its research focuses on human antibodies that target protein aggregation diseases, including Alzheimer’s disease, amyotrophic lateral sclerosis and ATTR cardiomyopathy.

Research instituteAntibody therapeuticsDrug candidates in clinical developmentReverse Translational Medicine™ (RTM™)

Sudo AI GmbH

Since 2025 · 1–10 empl.

Sudo AI GmbH develops robotic systems combining in-house hardware and software with AI models for physical manipulation. Its #sudo R1 system focuses on object picking and is trained exclusively on simulation data.

Research instituteRobotic Picking System (sudo R1)Simulation-based Robotics DevelopmentBrand and Media Support

Proxima Bio GmbH

Since 2026 · 21–50 empl.

Proxima Bio GmbH develops AI-based methods for drug discovery, including tools to predict molecular structures and design biomolecules. Its work combines Neo-1, a model for structure prediction and molecular design, with NeoLink, a platform that generates structural data using cross-linking mass spectrometry.

Research instituteAI-Enabled Drug Discovery and Molecular DesignStructural Proteomics and Cross-Linking Mass SpectrometryProtein Structure Prediction and Molecular Docking

CDDS AG

Since 2025 · 1–10 empl.

CDDS AG develops autonomous, AI-enabled interceptor drones and systems for countering unmanned aircraft. Its solutions detect, track and neutralize drone threats; launch stations store, charge and deploy interceptors and can integrate with existing command, radar and sensor systems.

Research instituteAutonomous Interceptor Drone (CDDS Aircraft)Interceptor and Launch System (CDDS System)

Arcnivaris Life Sciences GmbH

Since 2026 · 1–10 empl.

Arcnivaris Life Sciences GmbH is a consultancy for cosmetics and life sciences. It advises companies on assessing product directions, shaping product concepts and development pathways, and planning product claims and market entry.

Management consultantProduct Positioning AssessmentProduct Concept and Development PathRegulatory Positioning and Claims

C Bertozzi Services

Since 2026 · 1–10 empl.

C Bertozzi Services develops biological therapeutics for diseases of the central nervous system, with a focus on glioblastoma. The company is working on the C-Lock™ platform and the drug candidate InC01, a locally acting cytokine therapy designed for targeted immune activation in the brain.

Research instituteC-Lock Biologics DevelopmentGlioblastoma Therapy (InC01)Clinical Development for CNS Diseases

ALP Bio AG

Since 2026 · 1–10 empl.

ALP Bio AG develops technologies to assess and reduce the immunogenicity risk of therapeutic antibodies. Its platform combines human tonsil-derived organoid models with protein AI for computational screening, experimental validation and antibody redesign.

Research instituteImmunogenicity Analysis and Optimization Platform

BK Energie Mess AG

Since 1992 · 1–10 empl.

BK Energie Mess AG carries out mobile energy and technical measurements, including flow, temperature, pressure, electricity and indoor climate measurements. It evaluates the data and prepares analyses to support operational optimisation and renovation projects.

Research instituteMobile ultrasonic flow measurementTemperature measurementPressure and differential pressure measurement

No score yet

DAiNA Laboratories AG

Since 2025 · 1–10 empl.

DAiNA Laboratories AG develops approaches for personalized cancer care. The company combines AI with molecular data and biological analyses to characterize tumors individually and support treatment decisions.

Research institutePersonalized Oncology PlatformN=1 MedicinePersonalized Cancer Therapies

No score yet